Neogen Q1 2027: Revenue and EPS Both Clear Estimates
As seen on the 24/7 Wall St. homepage on October 6, 2026.
Neogen raised full-year revenue guidance to $885 million to $890 million after beating on both lines, so anyone waiting on the sidelines is missing the turn. The Zoetis genomics sale is still set to close by December.
Continue ReadingShow less
Neogen posted first-quarter fiscal 2027 revenue of $222.8 million, exceeding expectations, with adjusted EPS of $0.08 also topping estimates. Revenue grew 6.5% year over year, a pace strong enough to prompt management to raise full-year guidance.
Gross margin expanded to 47.4% from 45.4% a year ago, with the primary driver being a steep decline in costs tied to integrating the 3M food safety business. Adjusted EBITDA reached $41.6 million at an 18.7% margin.
The Food Safety segment led the way with $163.2 million in revenue, up 7.4%, powered by Petrifilm and pathogen detection products. Animal Safety added $59.6 million, up 4.2%. Geographically, international demand was a notable bright spot, with the Asia Pacific region posting double-digit growth.
Management lifted full-year revenue guidance to a range of $885 million to $890 million and raised Adjusted EBITDA guidance. The company also said it remains on track to begin manufacturing saleable Petrifilm product in November 2026 as part of a planned multi-quarter transition to its Lansing facility.
The pending sale of the global Genomics business to Zoetis is expected to close by the end of December 2026, which remains a key event for investors to monitor. Management flagged that the quarter included roughly a 3% core revenue benefit from prior-year distributor inventory adjustments and the timing of customer orders, so the underlying organic run rate is somewhat softer than the headline number implies.
Mentioned: NEOG